GeoVax Commences Site Expansion For Phase 2 Trial Of Next-Generation Covid-19 Vaccine
GEOVAX LABS INC +1.56%
GEOVAX LABS INC GOVX | 1.95 | +1.56% |
Designed to Protect Immunocompromised Patients Against Severe COVID-19
GeoVax Commences Site Expansion For Phase 2 Trial Of Next-Generation Covid-19 Vaccine
GEOVAX LABS INC GOVX | 1.95 | +1.56% |
Designed to Protect Immunocompromised Patients Against Severe COVID-19